PNC Financial Services reduced its holdings in Regeneron Pharmaceuticals by 8.8% in the fourth quarter, selling 1,608 shares. Other institutional investors have also adjusted their positions, with ...

Lifeworks Advisors LLC increased its stake in Regeneron Pharmaceuticals by 31.5%, now holding 6,743 shares worth $4.8 million ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average rating of “Moderate Buy” from the ...